Please use this identifier to cite or link to this item:
Title: Intradermal zoster vaccines: good for the old and the young?
Authors: Ogunjimi, Benson
HENS, Niel 
Issue Date: 2016
Source: LANCET INFECTIOUS DISEASES, 16(8), p. 869-871
Abstract: In The Lancet Infectious Diseases, Chan R Beals and colleagues report the results of a clinical trial in which varicella-zoster virus specific immunogenicity and adverse events were compared between the Merck live attenuated full dose subcutaneous herpes zoster vaccine, 1/3 subcutaneous zoster vaccine, full dose intradermal zoster vaccine, 1/3 intradermal zoster vaccine, 1/10 intradermal zoster vaccine, and 1/27 intradermal zoster vaccine. Full and 1/3 intradermal zoster vaccine caused a significantly higher increase in varicella-zoster virus antibody titer (measured by gpELISA) 6 weeks after vaccination compared with full subcutaneous zoster vaccine (p<0.0001 for full intradermal zoster vaccine and p=0.007 for the 1/3 intradermal zoster vaccine). In a subgroup analysis, it was shown that after 18 months the gpELISA zoster vaccine titre was still higher after full and 1/3 intradermal zoster vaccine compared with full subcutaneous varicella-zoster vaccine.
Notes: [Ogunjimi, Benson; Hens, Niel] Univ Antwerp, Antwerp, Belgium. [Hens, Niel] Hasselt Univ, Ctr Stat, Martelarenlaan 42, B-3500 Hasselt, Belgium.
Document URI:
ISSN: 1473-3099
e-ISSN: 1474-4457
DOI: 10.1016/S1473-3099(16)00174-2
ISI #: 000382215700007
Category: A1
Type: Journal Contribution
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
Ogunjimi and Hens 2016.pdf
  Restricted Access
Published version309.27 kBAdobe PDFView/Open    Request a copy
Ogunjimi and Hens TLID comment 2016 - auteursversie.pdfPeer-reviewed author version56.17 kBAdobe PDFView/Open
Show full item record

Page view(s)

checked on May 27, 2022


checked on May 27, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.